PROALT attended and exhibited at BIO 2015 International Convention

18th, June 2015
PROALT has participated in BIO International Convention 2015. This year’s event has been held from 15 to 18 June 2015 in Philadelphia (United States). The Spanish Pavillion was organized by ICEX (Spain Trade and Investment) and The Spanish Trade Commission in Chicago, and brought together other 52 companies and Spanish biotech institutions.

PROALT presented its COLODETECT test for early diagnosis of colorectal cancer in population at risk. Colodetect test is non-invasive, low cost and easy to use for screening of large populations at risk, compared with high complexity tools (colonoscopy/sigmoidoscopy), and will achieve good detection capacity at early stages, which involve better treatment options to improve patient’s survival. Colodetect is in prototype validation phase.

PROALT also presented its monoclonal antibody αCDH17 to companies interested to partner with PROALT for future development. Monoclonal antibody αCDH17 has been developed and patented by PROALT for inhibition/treatment of liver metastases from colorectal cancer. This monoclonal antibody αCDH17 is in preclinical phase.

Finally, PROALT showed its catalog of products, recombinant proteins and antibodies for research, as well as its contract research services for biopharmaceutical companies and research centers.

About BIO 2015: The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
http://convention.bio.org/about-bio-convention/

About PROALT: Protein Alternatives (PROALT) is a biotechnology company founded in 2006 and located in the city of Tres Cantos, Madrid. PROALT is a focused on the development and commercialization of biomarker-based assays for cancer diagnosis and clinical management. The company also offers its own manufactured innovative recombinant proteins and antibodies, and different custom-tailored integral services in protein design and expression. Service offer is performed under individual customer contracts (CRO) to meet biotechnology industry needs.
http://www.proteinalternatives.com/